Condition

Stage IV Renal Cell Cancer

ClinicalTrials.gov condition label

Clinical trials21
Recruiting0
Common interventions25
Lead sponsors shown11

Clinical trials

21 shown
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor SitesNCT04267575 · 2019-07-30
UNKNOWN
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsNCT03682289 · 2019-01-17
ACTIVE_NOT_RECRUITING
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaNCT03229278 · 2017-10-03
COMPLETED
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerNCT03154190 · 2017-08-08
COMPLETED
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsNCT02650635 · 2016-02-05
TERMINATED
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsNCT02646319 · 2016-01-01
COMPLETED
18F-FSPG PET/CT for Cancer Patients on TherapyNCT02599194 · 2015-07-01
COMPLETED
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerNCT02273752 · 2014-11-01
TERMINATED
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung CancersNCT01846520 · 2013-10-29
COMPLETED
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyNCT01806675 · 2013-03-04
COMPLETED
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerNCT01727076 · 2013-02-15
COMPLETED
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT01548482 · 2012-03-01
COMPLETED
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsNCT01155258 · 2010-06-01
COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsNCT01131234 · 2010-05-01
COMPLETED
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerNCT00937482 · 2009-08-01
TERMINATED
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyNCT00890747 · 2009-08-01
COMPLETED
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryNCT00348699 · 2006-07-01
COMPLETED
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNCT00101348 · 2005-01-01
COMPLETED
Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsNCT00655655 · 2004-12-01
COMPLETED
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsNCT00089362 · 2004-07-01
COMPLETED
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNCT00004074 · 1999-08-01
COMPLETED

Common interventions

Laboratory Biomarker AnalysisOTHER12Pharmacological StudyOTHER8cediranib maleateDRUG2EverolimusDRUG2temsirolimusDRUG218F-FDGDRUG118F-fludeoxyglucose (18F-FDG)DRUG118F-FPPRGD2DRUG118F-FSPGDRUG1ABI-007/carboplatin/trastuzumabBIOLOGICAL1AFP464DRUG1alvespimycin hydrochlorideDRUG1Best PracticeOTHER1bevacizumabBIOLOGICAL1Canady Helios Cold Plasma ScalpelDEVICE1CeralasertibDRUG1cetuximabBIOLOGICAL1CyclophosphamideDRUG1DurvalumabDRUG1dynamic contrast-enhanced magnetic resonance imagingPROCEDURE1educational interventionOTHER1Enzyme Inhibitor TherapyDRUG1erlotinib hydrochlorideDRUG1Gamma-Secretase Inhibitor RO4929097DRUG1Nanoparticle Albumin-Bound RapamycinDRUG1

Trial status mix

COMPLETED16
TERMINATED3
ACTIVE_NOT_RECRUITING1
UNKNOWN1

Phase mix

PHASE114
PHASE25
NA3
EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.